TNFRSF4 and brain neoplasm: Similarly, mice bearing intracranial GL261 cell-based brain tumors and treated with a combination of OX40 mAb, local cranial radiotherapy, as well as intrasplenic vaccination with DC demonstrated the complete regression of tumor resulting in long-term survival (≥120 days) with no evidence of tumor recurrence and resistance to further intracranial tumor challenge (Kjaergaard et al., 2005).